Journal of Cardiac Failure
Volume 16, Issue 10 , Pages 812-822 , October 2010

Clinical Features of Myocardial Triglyceride in Different Types of Cardiomyopathy Assessed by Proton Magnetic Resonance Spectroscopy: Comparison With Myocardial Creatine

  • Ichiro Nakae, MD

      Affiliations

    • Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Kenichi Mitsunami, MD

      Affiliations

    • Department of Family Medicine, Shiga University of Medical Science, Shiga, Japan
    • Corresponding Author InformationReprint requests: Kenichi Mitsunami, MD, Department of Family Medicine, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan. Tel: +81-77-548-2598; Fax: +81-77-548-9701.
    • ,
  • Tomohide Yoshino, MD

      Affiliations

    • Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Tomoko Omura, MD

      Affiliations

    • Omura Clinic, Shiga, Japan
    • ,
  • Takayoshi Tsutamoto, MD

      Affiliations

    • Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Tetsuya Matsumoto, MD

      Affiliations

    • Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Shigehiro Morikawa, MD

      Affiliations

    • Department of Fundamental Nursing, Morphology & Physiology, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Toshiro Inubushi, PhD

      Affiliations

    • Biomedical MR Science Center, Shiga University of Medical Science, Shiga, Japan
    • ,
  • Minoru Horie, MD

      Affiliations

    • Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Shiga, Japan

Received 24 November 2009 ,Revised 28 February 2010 ,Accepted 7 May 2010.

References 

  1. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813–822
  2. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692–1700
  3. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003;144:3483–3490
  4. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417–423
  5. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101:759–767
  6. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med. 2006;144:517–524
  7. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52:1006–1012
  8. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest. 1999;115:836–847
  9. Kalra PR, Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol. 2002;85:125–132
  10. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135–145
  11. Neubauer S. The failing heart- an engine out of fuel. N Engl Med. 2007;356:1140–1151
  12. Neubauer S, Hamman BL, Perry SB, Brittl JA, Ingwall JS. Velocity of the CK reaction decreases in postischemic myocardium: a magnetization transfer study of the isolated ferret heart. Circ Res. 1988;63:1–15
  13. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 1996;94:1894–1901
  14. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, et al. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol. 2005;39:537–544
  15. Bottomley PA, Weiss RG. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet. 1998;351:714–718
  16. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587–1593
  17. Nakae I, Mitsunami K, Matsuo S, Inubushi T, Morikawa S, Tsutamoto T, et al. Myocardial creatine concentration in various nonischemic heart diseases assessed by 1H magnetic resonance spectroscopy. Circ J. 2005;69:711–716
  18. Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG, Szczepaniak LS. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab. 2005;289:E935–E939
  19. Ugolini V, Hansen CL, Kulkarni P, Jansen DE, Akers MS, Corbett JR. Abnormal myocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenyl-pentadecanoic acid tomographic imaging. Am J Cardiol. 1988;62:923–928
  20. Nakae I, Matsuo S, Koh T, Mitsunami K, Horie M. Iodine-123 BMIPP scintigraphy in the evaluation of patients with heart failure. Acta Radiol. 2006;47:810–816
  21. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574–581
  22. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–543
  23. Nakae I, Mitsunami K, Matsuo S, Matsumoto T, Morikawa S, Inubushi T, et al. Assessment of myocardial creatine concentration in dysfunctional human heart by proton magnetic resonance spectroscopy. Magn Reson Med Sci. 2004;3:19–25
  24. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation. 1995;92:15–23
  25. Schick F, Eismann B, Jung W-I, Bongers H, Bunse M, Lutz O. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med. 1993;29:158–167
  26. Nakae I, Mitsunami K, Yabe T, Inubushi T, Morikawa S, Matsuo S, et al. Detection of metabolic abnormality in asynergic regions of ischemic human myocardium using 31P and 1H magnetic resonance spectroscopy. J Cardiovasc Magn Reson. 2004;6:685–696
  27. Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, et al. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of β-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med. 1997;24:523–529
  28. van der Meer RW, Rijzewijk LJ, Diamant M, Hammer S, Schär M, Bax JJ, et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J. 2008;29:1516–1522
  29. Nohara R. Lipid metabolism in the heart—contribution of BMIPP to the diseased heart. Ann Nucl Med. 2001;15:403–409
  30. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093–1129
  31. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension. 2004;44:662–667
  32. Takeishi Y, Chiba J, Abe S, Tonooka I, Komatani A, Tomoike H. Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy. Eur J Med. 1992;19:775–782
  33. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002;51:2587–2595
  34. Cree MG, Newcomer BR, Katsanos CS, Sheffield-Moore M, Chinkes D, Aarsland A, et al. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab. 2004;89:3864–3871
  35. Nakamura T, Sugihara H, Kinoshita N, Yoneyama S, Azuma A, Nakagawa M. Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts?. Hypertension. 2000;36:215–219
  36. Carvajal K, Moreno-Sanches R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res. 2003;34:89–99
  37. Tian R, Ingwall JS. The molecular energetics of the failing heart from animal models- small animal models. Heart Failure Rev. 1999;4:235–253
  38. Zhang J, Bache RJ. The molecular energetics of the failing heart from animal models- large animal models. Heart Failure Rev. 1999;4:255–267
  39. Okada M, Mitsunami K, Inubushi T, Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: contents of phosphorus metabolites measured by 31P MRS. Magn Reson Med. 1998;39:772–782
  40. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867–1876
  41. Neubauer S, Remkes H, Spindler M, Horn M, Weismann F, Prestle J, et al. Downregulation of the Na+-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation. 1999;100:1847–1850
  42. Hove MT, Chan S, Lygate C, Monfared M, Boehm E, Hulbert K, et al. Mechanisms of creatine depletion in chronically failing rat heart. J Moll Cell Cardiol. 2005;38:309–313
  43. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190–2196
  44. Bilheimer DW, Buja LM, Parkey RW, Bonte FJ, Willerson JT. Fatty acid accumulation and abnormal lipid deposition in peripheral and border zones of experimental myocardial infarcts. J Nucl Med. 1978;19:276–283
  45. Straeter-Knowlen IM, Evanochko WT, den Hollander JA, Wolkowicz PE, Balschi JA, Caulfield JB, et al. 1H NMR spectroscopic imaging of myocardial triglycerides in excised dog hearts subjected to 24 hours of coronary occlusion. Circulation. 1996;93:1464–1470
  46. Baroldi G, Silver MD, De Maria R, Parodi O, Pellegrini A. Lipomatous metaplasia in left ventricular scar. Can J Cardiol. 1997;13:65–71
  47. Brittl JA, Ingwall JS. Reaction rates of creatine kinase and ATP synthesis in the isolated rat heart. J Biol Chem. 1985;260:3512–3517
  48. Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging. 2009;30:145–152
  49. Germano G, Kiat H, Kavanagh P, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med. 1995;36:2138–2147
  50. Nakae I, Matsuo S, Koh T, Mitsunami K, Horie K. Left ventricular systolic/diastolic function evaluated by quantitative ECG-gated SPECT: comparison with echocardiography and plasma BNP analysis. Ann Nucl Med. 2005;19:447–454

 See page 821 for disclosure information.

PII: S1071-9164(10)00212-5

doi: 10.1016/j.cardfail.2010.05.006

Journal of Cardiac Failure
Volume 16, Issue 10 , Pages 812-822 , October 2010

Article Tools

* Image Usage & Resolution